Exchange: NYSE·Updated 07:50 PM EDT
ANVS logo

ANVS Annovis Bio Inc

$1.72
$0.09
(4.97%)
Today
Closed $1.72
$0.0299
(1.74%)
After Hours
Reported EarningsAug 14
Mkt Cap$73.28M
Vol504,513.00

About ANVS

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
32

Bearish Sentiment

How do you feel about ANVS?

Advertisement|Remove ads.